The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis
Status and phase
Conditions
Treatments
Details and patient eligibility
About
Hemoptysis is defined as the expectoration of blood from respiratory tract, a spectrum that varies from blood-streaking of sputum to coughing up large amounts of pure blood.
Massive hemoptysis variably defined as the expectoration of 100-600 ml over 24-h period.
The most common site of bleeding is the tracheobronchial tree, which can be affected by inflammation (acute or chronic bronchitis, bronchiectasis) or by neoplasm ( bronchogenic carcinoma, endobronchial metastatic carcinoma, bronchial carcinoid tumor). The bronchial arteries, which originate either from aorta or from intercostal arteries, and are part of the high-pressure systemic circulation, are the source of bleeding in bronchitis or bronchiectasis or endo bronchial tumors.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Age > 18
- Hemodynamicaly stable
- Hemoptysis of varying etiologies
- Coumadin treatment will be switched to clexane or heparine
Exclusion criteria
- Age < 18
- Hemodinamicaly unstable
- Massive hemoptysis ( > 200 ml / day)
- Renal failure: creatinine > 3, renal replacement treatment
- Hepatic failure: bilirubin > 2 mg/dl, AST > 3 of upper normal limit level
- Coagulation disorders, INR> 2.
- Hypesensitivity to tranexamic acid
- Pregnant woman
Trial design
Primary purpose
Allocation
Interventional model
Masking
100 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Central trial contact
David Shitrit, Dr.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal